A 80915A

A 80915A, with CAS number 127875-60-9, is a naturally derived semi-naphthoquinone antibiotic, originally isolated from the actinobacterium Streptomyces aculeolatus. Its chemical identity is defined by the IUPAC name: 2H-naphtho(2,3-b)pyran-5,10-dione, 3,4a-dichloro-10a-((3-chloro-2,2-dimethyl-6-methylene cyclohexyl)methyl)-3,4,4a,10a-tetrahydro-6,8-dihydroxy-2,2,7-trimethyl-, and it has a molecular formula of C₂₆H₃₁Cl₃O₅ with a molecular weight of 529.88.
This compound is primarily recognized for its biological activity targeting gastric physiology, specifically as an inhibitor of gastric (H⁺-K⁺)-ATPase. Early research into its mechanism revealed unique interactions with this enzyme—unlike many conventional inhibitors, its activity is closely tied to the conformational state of (H⁺-K⁺)-ATPase, and ions like potassium can modulate its inhibitory efficiency by altering the enzyme’s structure to reduce drug binding accessibility.
Synonyms for A 80915A include A 80915 a and A-80915 a, reflecting minor variations in formatting across scientific literature and supplier documentation. Its discovery emerged from efforts to identify natural product-based modulators of acid secretion pathways, a focus area in both pharmaceutical research and basic enzymology.

Classified as a semi-naphthoquinone antibiotic, distinguishing it from fully synthetic inhibitors of gastric (H⁺-K⁺)-ATPase and linking it to a class of natural products with diverse biological activities.
Exhibits a specific mode of action dependent on the conformation of gastric (H⁺-K⁺)-ATPase, with no evidence of covalent modification of the enzyme—differentiating it from proton pump inhibitors like omeprazole.
Maintains high purity standards, typically exceeding 98% as verified by certificates of analysis, ensuring reliability for experimental applications.
Physically exists as a solid powder, with solubility in DMSO (dimethyl sulfoxide) enabling straightforward formulation for in vitro and biochemical assays.
Demonstrates concentration-dependent inhibition of gastric (H⁺-K⁺)-ATPase, with an IC₅₀ of approximately 2-3 μM for both ATPase and p-nitrophenyl phosphatase activities.

Biochemical Enzymology Research: Used to probe the structure-function relationship of gastric (H⁺-K⁺)-ATPase, particularly in understanding how ion-dependent conformational changes regulate enzyme activity.
Comparative Pharmacology Studies: Serves as a reference compound to contrast inhibition mechanisms with other proton pump inhibitors (e.g., omeprazole, SCH 28080) for drug discovery and mode-of-action analysis.
Antibacterial Mechanism Investigations: Supports research into the broader biological roles of semi-naphthoquinone antibiotics from Streptomyces species, beyond their activity on gastric enzymes.
In Vitro Assay Development: Validated for use in potassium-stimulated ATP hydrolysis and p-nitrophenolphosphate assays, making it suitable for high-throughput screening of (H⁺-K⁺)-ATPase modulators.
Pharmaceutical Preclinical Research: Utilized in early-stage studies exploring new therapeutic approaches for acid-related gastric disorders by targeting (H⁺-K⁺)-ATPase.

In the field of gastric (H⁺-K⁺)-ATPase research and semi-naphthoquinone natural products, customers often seek complementary compounds such as specific proton pump inhibitors with distinct mechanisms (e.g., SCH 28080), other Streptomyces-derived semi-naphthoquinone antibiotics, and biochemical reagents for assaying ATPase activity (e.g., potassium-stimulated ATP substrates, p-nitrophenolphosphate). Additionally, related inhibitors of acid secretion pathways, including histamine H₂ receptor antagonists and muscarinic receptor blockers, are of interest for comparative physiological studies. If you are interested in related products, you can directly contact us for product customization services.